GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » EPS without NRI
中文

Invitae (Invitae) EPS without NRI : $-1.59 (TTM As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Invitae EPS without NRI?

Invitae's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-0.26. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.59.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -6.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Invitae's EPS without NRI or its related term are showing as below:

NVTAQ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -76.5   Med: -16.1   Max: 15.2
Current: -6.3

During the past 11 years, Invitae's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 15.20% per year. The lowest was -76.50% per year. And the median was -16.10% per year.

NVTAQ's 3-Year EPS without NRI Growth Rate is ranked worse than
63.22% of 174 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.25 vs NVTAQ: -6.30

Invitae's EPS (Diluted) for the three months ended in Sep. 2023 was $-3.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.38.

Invitae's EPS (Basic) for the three months ended in Sep. 2023 was $-3.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.38.


Invitae EPS without NRI Historical Data

The historical data trend for Invitae's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae EPS without NRI Chart

Invitae Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.94 -2.66 -3.89 -3.58 -3.19

Invitae Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.74 -0.34 -0.52 -0.48 -0.26

Competitive Comparison of Invitae's EPS without NRI

For the Diagnostics & Research subindustry, Invitae's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitae's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Invitae's PE Ratio without NRI falls into.



Invitae EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invitae  (OTCPK:NVTAQ) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Invitae EPS without NRI Related Terms

Thank you for viewing the detailed overview of Invitae's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitae (Invitae) Business Description

Traded in Other Exchanges
Address
1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
Executives
Ana J. Schrank officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley officer: Chief Commercial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey officer: See Remarks 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons officer: See remarks 2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum officer: Chief Medical Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida officer: General Counsel 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight officer: Chief Operating Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne director 1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George director, officer: CEO 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer officer: Chief Financial Officer 1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland officer: Chief Commercial Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse director 3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers director, other: President, Oncology C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301

Invitae (Invitae) Headlines

From GuruFocus

Q4 2019 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2021 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2021 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024